Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial In Ulcerative Colitis With Novel Oral Anti-Inflammatory Drug Candidate TRIOLEX(TM)

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that it has commenced a Phase I/II clinical trial with its oral drug candidate TRIOLEX? (HE3286) in ulcerative colitis (UC) under an Investigational New Drug application (IND) cleared by the U.S. Food and Drug Administration (FDA) for this indication.

More: continued here

Filed under: Clinical Trials on February 11th, 2008